A tool for targeted chemotherapy
A new test aims to identify which cancer patients benefit from being treated with ADCs.
Sofia Lindén is responsible for producing the content for digital communications in the cluster, including articles, photographs and videos for the websites and social media platforms.
She has previously worked at the Nordic publishing company Orage as Swedish Print Editor and Digital Project Manager. She also holds a master degree in International Journalism from City University London. Find out more about Sofia by visiting her LinkedIn.
A new test aims to identify which cancer patients benefit from being treated with ADCs.
A test that predicts which breast cancer patients benefit from chemotherapy has been approved.
Three leading immunotherapy drugs against lung cancer demonstrated similar overall survival in a recent comparative study from NordicRWE. The Norwegian start-up company NordicRWE has compared the effectiveness of three immunotherapies in second line treatment of advanced non-small cell lung cancer. The results indicate that the three immunotherapy drugs were equally effective in terms of overall […]
Transforming the area into an international power centre for cancer research.
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.